OPRX — OptimizeRx Corporation

Summary of OptimizeRx Q1 2026 Earnings Call

1. Key Financial Results and Metrics:

• Revenue: $19.8 million, a decrease of 10% from $21.9 million in Q1 2025.
• Adjusted EBITDA: $3.3 million, up from $1.5 million year-over-year.
• Net Loss: Narrowed to $0.5 million ($0.03 per share) from a loss of $2.2 million ($0.12 per share) in the prior year.
• Non-GAAP Net Income: Increased to $2.7 million ($0.14 per share) from $1.5 million ($0.08 per share).
• Cash Balance: $20.2 million at quarter-end, down from $23.4 million at the end of 2025.
• Debt: $23.6 million, with a recent refinancing expected to reduce interest expenses by approximately $1.5 million annually.

2. Strategic Updates and Business Highlights:

• The company is experiencing a shift towards digital, data-driven engagement in life sciences, with a 60% growth in their AI-enabled Digital Activation Platform (DAP).
• Subscription revenue from DAP grew by 45%, indicating a successful transition towards more predictable revenue models.
• The company is expanding its presence with mid-tier and long-tail life science companies, which represent significant growth opportunities.
• OptimizeRx is enhancing its platform to connect with demand-side platforms (DSPs), potentially increasing revenue through programmatic access to its network.

3. Forward Guidance and Outlook:

• Updated Revenue Guidance: Expected to be in the range of $95 million to $100 million for the full year 2026, reflecting a more conservative outlook.
• Adjusted EBITDA Guidance: Maintained at $21 million to $25 million, indicating confidence in operational strength and cost optimization efforts.
• Revenue is expected to be weighted towards the second half of the year, with a 40/60 split.

4. Bad News, Challenges, or Points of Concern:

• Revenue decline attributed to ongoing softness in contracted revenue, driven by macroeconomic factors and disruptions related to Most Favored Nation pricing.
• Contract durations have shortened, leading to less visibility and uncertainty in revenue forecasting.
• One major client is experiencing challenges, impacting overall growth; management acknowledges execution issues and is working to improve the relationship.
• Despite positive growth in certain areas, the company faces headwinds that could affect performance in the near term.

5. Notable Q&A Insights:

• Management clarified that the revised revenue guidance is due to delays in decision-making and shorter contract commitments from clients, particularly in the pharmaceutical sector.
• There is confidence that current pressures are short-term, with expectations for increased buying activity in the latter half of 2026.
• The connection to DSPs is seen as a significant growth opportunity, with initial revenue expected to flow in Q4 2026.
• The company is focused on improving engagement with clients and addressing execution issues to ensure better performance moving forward.

Overall, while OptimizeRx has shown operational strength and growth in specific areas, it is navigating short-term challenges that have led to a more cautious revenue outlook for 2026.